Along these lines, recent studies from our group have shown that the anti-angiogenic activity observed with MEK inhibitors in melanoma models in vitro and in vivo (105) is due, at least in part, to MEK inhibition-induced upregulation of PTEN expression. Here, PTEN is linked to melanoma.